The levels of HA and its receptor CD44 in tumor cells are predictive of malignancy and often correlate with cancer aggressiveness in patients with glioblastoma, breast, prostate and non-small cell lung cancers [15,16,19-23]. This evidence concerns the gene CD44 and neoplasm.